Navigation Links
BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Date:7/28/2009

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-877-627-6566 (United States) or 1-719-325-4922 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for at least 14 days.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in oncology, infectious and autoimmune diseases. BioCryst has two product candidates in pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to expand its portfolio of next-generation therapeutic candidates with the potential to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings, Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at www.shareholder.com/biocryst/edgar.cfm.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
4. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
7. BioCryst to Present at the JMP Healthcare Focus Conference
8. BioCryst to Present at UBS 2008 Global Life Sciences Conference
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)...  Rhythm, a biopharmaceutical company developing peptide ... in life-threatening metabolic disorders, today announced the ... of financing with existing investors including Deerfield ... Associates, Pfizer Venture Investments, Third Rock Ventures, ... Rhythm will use the proceeds to advance ...
(Date:2/15/2017)... SAN FRANCISCO , 15. Februar 2017 /PRNewswire/ ... mit Janssen Biotech, Inc. (Janssen) eine Lizenzvereinbarung über ... in ihrer Klasse führenden Plattform für die Entdeckung ... sich durch ihr neuartiges chimäres Gensegmentdesign aus, das ... Auswahl an humanen Antikörpern bietet und das für ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... its sixth annual open house and technology show, Morris Madness, March 14-15, 2017 ... cutting demos from Okuma, Tsugami and Hardinge Group in addition to displays of ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
Breaking Biology News(10 mins):